Survival time correlated with clinical parameters (pancreatic cancer patient age, serum galectin‐3 level, CA19‐9 and CEA levels, TNM stage, liver or lymph node metastasis, and treatment; P < .05, Table S4). The gene discussed is CEACAM5; the disease is metastatic malignant neoplasm in the lymph nodes.